MN-447 and MN-462 are anti-clotting agents that represent novel approaches to blood clot formation and are expected to treat a variety of thrombotic disorders. Both agents have demonstrated new mechanisms of action against blood clot formation in preclinical studies.
“MN-447 and MN-462 represent potentially important new interventions to treat thrombosis-related cardiovascular diseases, and commercially valuable additions to MediciNova’s advancing portfolio of product candidates,” said Yuichi Iwaki, CEO of MediciNova. “MediciNova continues to execute its business strategy to in-license and develop differentiated, high quality assets with broad intellectual property rights and large commercial potential through alliances with Japanese pharmaceutical partners.”
MediciNova acquired a license to MN-447 and MN-462 from Meiji Seika Kaisha for global markets, with the exception of Japan and other selected Asian countries. The data acquired from Meiji Seika Kaisha includes extensive preclinical efficacy and safety data. Terms of the licensing were not disclosed.